291 related articles for article (PubMed ID: 22714051)
21. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2010 Nov; 1360():193-7. PubMed ID: 20833153
[TBL] [Abstract][Full Text] [Related]
22. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.
Pardridge WM
BioDrugs; 2017 Dec; 31(6):503-519. PubMed ID: 29067674
[TBL] [Abstract][Full Text] [Related]
23. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
[TBL] [Abstract][Full Text] [Related]
24. Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins.
Pardridge WM
Adv Exp Med Biol; 2002; 513():397-430. PubMed ID: 12575830
[TBL] [Abstract][Full Text] [Related]
25. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system.
Zhang Y; Pardridge WM
Stroke; 2001 Jun; 32(6):1378-84. PubMed ID: 11387502
[TBL] [Abstract][Full Text] [Related]
26. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.
Sumbria RK; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Mol Pharm; 2013 Sep; 10(9):3507-13. PubMed ID: 23924247
[TBL] [Abstract][Full Text] [Related]
27. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.
Chang R; Al Maghribi A; Vanderpoel V; Vasilevko V; Cribbs DH; Boado R; Pardridge WM; Sumbria RK
Mol Pharm; 2018 Nov; 15(11):4963-4973. PubMed ID: 30252487
[TBL] [Abstract][Full Text] [Related]
28. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein.
Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Drug Metab Dispos; 2011 Jul; 39(7):1149-54. PubMed ID: 21502195
[TBL] [Abstract][Full Text] [Related]
29. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.
Fu A; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2010 Sep; 1352():208-13. PubMed ID: 20599807
[TBL] [Abstract][Full Text] [Related]
30. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2012 Feb; 40(2):329-35. PubMed ID: 22065691
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of a Brain-Penetrant Biologic TNF-α Inhibitor in Aged APP/PS1 Mice.
Ou W; Ohno Y; Yang J; Chandrashekar DV; Abdullah T; Sun J; Murphy R; Roules C; Jagadeesan N; Cribbs DH; Sumbria RK
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297637
[TBL] [Abstract][Full Text] [Related]
32. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Feldmann M; Maini RN
Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
[TBL] [Abstract][Full Text] [Related]
33. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
Boado RJ; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
[TBL] [Abstract][Full Text] [Related]
34. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein.
Lee JH; Cho JH; Yeo J; Lee SH; Yang SH; Sung YC; Kang JH; Park CS
Biologicals; 2013 Mar; 41(2):77-83. PubMed ID: 23190454
[TBL] [Abstract][Full Text] [Related]
35. Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice.
Yang J; Sun J; Castellanos DM; Pardridge WM; Sumbria RK
Mol Pharm; 2020 Aug; 17(8):2831-2839. PubMed ID: 32579360
[TBL] [Abstract][Full Text] [Related]
36. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis.
Plessner HL; Lin PL; Kohno T; Louie JS; Kirschner D; Chan J; Flynn JL
J Infect Dis; 2007 Jun; 195(11):1643-50. PubMed ID: 17471434
[TBL] [Abstract][Full Text] [Related]
37. IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport.
Boado RJ
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890374
[TBL] [Abstract][Full Text] [Related]
38. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.
Boado RJ; Hui EK; Lu JZ; Sumbria RK; Pardridge WM
Bioconjug Chem; 2013 Oct; 24(10):1741-9. PubMed ID: 24059813
[TBL] [Abstract][Full Text] [Related]
39. Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice.
Sun J; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2019 Aug; 16(8):3534-3543. PubMed ID: 31199881
[TBL] [Abstract][Full Text] [Related]
40. A recombinant tumor necrosis factor-alpha p80 receptor:Fc fusion protein decreases circulating bioactive tumor necrosis factor-alpha but not lung injury or mortality during immunosuppression-related gram-negative bacteremia.
Lechner AJ; Johanns CA; Matuschak GM
J Crit Care; 1997 Mar; 12(1):28-38. PubMed ID: 9075062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
